Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 1/20 | 0.56 |
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.47 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19729000 | 0.88 | FADS1 (0.55) | MAPKAPK2KDRPTK6RAF1BRAF | |
| SCHEMBL17846020 | 0.85 | EGFR (0.57) | CD38KDRRAF1BRAFEGFR | |
| SCHEMBL29667097 | 0.85 | EGFR (0.57) | CD38KDRRAF1BRAFEGFR | |
| SCHEMBL19729014 | 0.84 | MAPKAPK2 (0.45) | CD38MAPKAPK2KDRRAF1BRAF | |
| SCHEMBL19729031 | 0.81 | FADS1 (0.51) | CD38MAPKAPK2KDRPTK6RAF1 | |
| SCHEMBL19729035 | 0.77 | CD38 (0.66) | CD38MAPKAPK2PTK6RAF1BRAF | |
| SCHEMBL19729003 | 0.77 | CD38 (0.69) | CD38MAPKAPK2PTK6RAF1BRAF | |
| SCHEMBL19729008 | 0.76 | CD38 (0.65) | CD38MAPKAPK2PTK6RAF1BRAF | |
| SCHEMBL4740968 | 0.74 | CD38 (0.65) | CD38MAPKAPK2PTK6RIPK2EGFR | |
| SCHEMBL4961504 | 0.74 | CD38 (0.61) | CD38MAPKAPK2PTK6RIPK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | CD38 4006/4885MAPKAPK2 156/4885KDR 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.